Thrombosis Research 151, Suppl. 1 (2017) S1–S5

Contents lists available at ScienceDirect

Thrombosis Research

journal homepage: www.elsevier.com/locate/thromres

Uterine bleeding during anticoagulation in women with venous thromboembolism

Farès Moustafa [a,*], Sonia Fernández [b], Carmen Fernández-Capitán [c], José Antonio Nieto [d], José María Pedrajas [e], Adriana Visoná [f], Beatriz Valero [g], Pablo Javier Marchena [h], Andrei Braester [i], Manuel Monreal [j], and the RIETE Investigators**

[a]Department of Emergency, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
[b]Department of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Barcelona, Spain
[c]Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain
[d]Department of Internal Medicine, Hospital General Virgen de la Luz, Cuenca, Spain
[e]Department of Internal Medicine, Hospital Clínico San Carlos, Madrid, Spain
[f]Department of Vascular Medicine, Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy
[g]Department of Internal Medicine, Hospital General Universitario de Alicante, Alicante, Spain
[h]Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Deu-Hospital General, Barcelona, Spain
[i]Department of Haematology, Galilee Medical Center, Nahariya, Israel
[j]Department of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Barcelona, Universidad Católica de Murcia, Spain

ARTICLE INFO

Keywords:
Uterine bleeding
Anticoagulant therapy
Venous thromboembolism
A real-life study

ABSTRACT

Background: Women presenting with uterine bleeding during the course of anticoagulant therapy for venous thromboembolism (VTE) present a difficult therapeutic dilemma due to the absence of evidence-based recommendations.
Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to assess the clinical characteristics of women presenting with uterine bleeding during anticoagulation for VTE, its frequency, time course, management and 30-day outcomes.
Results: As of October 2016, 31,951 women with VTE were recruited in RIETE. During the course of anticoagulant therapy, 53 (0.17%) developed major uterine bleeding, 118 (0.37%) non-major uterine bleeding and 948 (2.97%) had major bleeding in other sites. Median time elapsed from VTE to bleeding was: 32, 71 and 22 days, respectively. Mean age was: 56 ± 17, 52 ± 20 and 75 ± 14 years, respectively. Women with major uterine bleeding more likely had cancer (51%), anemia (72%), raised platelet count (19%) or recent major bleeding (11%) at VTE presentation than those in the other subgroups. During the first 30 days after bleeding, 17%, 1.7% and 31% of women died, respectively. Of 11 women with uterine bleeding who died, 9 (82%) had cancer, two (18%) died of bleeding and one (9.1%) died of pulmonary embolism after discontinuing anticoagulation.
Conclusions: Uterine bleeding during the course of anticoagulation for VTE is not uncommon and mostly affects young women. Those with cancer, anaemia, raised platelet count or recent bleeding at baseline are at an increased risk for uterine bleeding during anticoagulation.

1. Introduction

Abnormal uterine bleeding is a relatively common complication in women receiving anticoagulant therapy for venous thromboembolism (VTE) [1–3]. In the literature, there is scarce information on its frequency, the clinical characteristics of these women, the time course and the severity of bleeding [1,4,5]. Most of the published information came from randomized clinical trials with strict inclusion and exclusion criteria, and limited follow-up [6]. Thus, although randomized clinical trials provide high-level evidence on the efficacy and safety of therapeutic interventions, they generally involve well-defined study populations that exclude complex patients and do not provide data on the management of bleeding [1,7,8]. This is important since uterine bleeding in women receiving anticoagulant therapy for VTE presents a dilemma because the potential benefits of anticoagulation must be weighed against the risk of inducing re-bleeding.

RIETE (Registro Informatizado Enfermedad TromboEmbólica) is a multicenter, ongoing, international (Spain, Belgium, Czech Republic, France, Greece, Israel, Italy, Latvia, Republic of Macedonia, Switzerland, United States, Canada, Ecuador and Venezuela enroll patients) observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE (ClinicalTrials.gov identifier: NCT02832245). Data from this registry have been used to evaluate outcomes after acute VTE, such as the frequency of recurrent VTE, bleeding and mortality, and risk factors for these outcomes [9–13].

* Corresponding author: Farès Moustafa, MD, Service des urgences, Hôpital Gabriel Montpied, 58 rue Montalembert, F-63003 Clermont-Ferrand Cedex 1, France. Tel.: +33 624366369.
E-mail address: fmoustafa@chu-clermontferrand.fr (F. Moustafa).
** A full list of RIETE investigators is given in the appendix.

0049-3848/$ – see front matter

Using the RIETE database, we retrospectively assessed the clinical characteristics of these women, the frequency and time course of bleeding, its management and the outcome within the first 30 days after bleeding.

2. Methods

2.1. Inclusion criteria

Consecutive patients with acute, symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) confirmed by objective tests (compression ultrasonography or contrast venography for DVT; helical CT-scan, ventilation–perfusion lung scintigraphy or angiography for PE) were enrolled in RIETE. Patients were excluded if they were currently participating in a therapeutic clinical trial with a blinded therapy. All patients (or their legal power of attorney) provided written or oral consent for participation in the registry, in accordance with local ethics committee requirements.

Physicians participating in the RIETE registry made all efforts to enroll consecutive patients. Data were recorded on to a computer-based case report form at each participating hospital and submitted to a centralized coordinating center through a secure website. To ensure the validity of the information entered into the database, one of the specially trained monitors visited each participating hospital and compared information in 25 to 50 randomly chosen patient records with the information entered into the RIETE database. For data quality assessment, monitors assessed 4,100 random records from all participating hospitals that included 1,230,000 measurements. These data showed a 95% overall agreement between the registered information and patient records. RIETE also used electronic data monitoring to detect inconsistencies or errors and attempted to resolve discrepancies by contacting the local coordinators.

2.2. Study design

We conducted a retrospective study that used prospectively collected data from consecutive patients enrolled in the RIETE registry. Major uterine bleeding was defined as an overt bleed that required a transfusion of two units or more of blood or was fatal. Clinically relevant non major uterine bleeding was defined as any bleeding requiring a medical intervention (hospitalization, surgery or interventional procedure, further diagnostic imaging, laboratory test or specialist evaluation) and/or treatment discontinuation, and not meeting any of the criteria for major bleeding. We compared the clinical characteristics of women with uterine bleeding during anticoagulation for VTE, its frequency, time course, management and 30-day outcomes vs. those in women presenting with major bleeding in other sites. We focused on the management of anticoagulant therapy after bleeding, not on other interventions (like surgery, hormonal therapy, etc.).

2.3. Baseline variables and definitions

The following parameters are routinely recorded in RIETE: patient's baseline characteristics; clinical status including any co-existing or underlying conditions; risk factors for VTE; diagnostics tools used for diagnosis; laboratory data; the treatment received upon VTE diagnosis (drugs, doses, regimen and duration); and the outcome during the course of anticoagulation. Age was divided in three categories (less than 35 years, 35 to 50 years and more than 50 years). Active cancer was defined as newly diagnosed cancer, metastatic cancer, or cancer that was being treated (i.e. surgery, chemotherapy, radiotherapy, support therapy). Anemia was defined as a hemoglobin content <13 g/dL for men and <12 g/dL for women.

2.4. Treatment and follow-up

Patients were managed according to the clinical practice of each participating centre (i.e., there was no standardization of treatment). Patients were followed-up during the course of therapy in the outpatient clinic or physician's office. During each visit, any signs or symptoms suggesting VTE recurrences or bleeding complications were noted. Each episode of clinically suspected recurrent VTE was investigated by repeat compression ultrasonography, lung scanning, helical-CT scan or pulmonary angiography, as appropriate. Most outcomes were classified as reported by the clinical centers. However, if staff at the coordinating center were uncertain how to classify a reported outcome, that event was reviewed by a central adjudicating committee (less than 10% of events).

2.5. Statistical analysis

Categorical variables were compared using the chi-square test (two-sided) and Fisher's Exact Test (two-sided). Continuous variables were compared using Student t test. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were calculated, and a p-value <0.05 was considered to be statistically significant. Statistical analyses were conducted with SPSS for Windows Release 17.0 (SPSS, Inc).

2.6. Role of the funding source

The sponsors of the RIETE registry (Sanofi and Bayer) had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results

As of October 2016, 31,951 women with VTE were recruited in RIETE. During the course of anticoagulant therapy, 53 (0.17%; 95% CI: 0.13–0.21) developed major uterine bleeding, 118 (0.37%; 95% CI: 0.31–0.44) had clinically relevant non major uterine bleeding and 948 (2.97%; 95% CI: 2.79–3.16) suffered major bleeding in other

Table 1
Clinical characteristics of the patients, according to severity and site of bleeding during the course of anticoagulant therapy.

	Major uterine bleeding	Non-major uterine bleeding	Major bleeding in other sites	No major bleeding in other sites
Patients, *N*	53	118	948	30,832
Clinical characteristics				
Mean age (years ± SD)	56 ± 17‡	52 ± 20‡	75 ± 14‡	67 ± 19
Age <35 years	4 (7.5%)	23 (19%)‡	27 (2.8%)‡	2,736 (8.9%)
Age 35–50 years	17 (32%)‡	44 (37%)‡	35 (3.7%)‡	3,672 (12%)
Age >50 years	32 (60%)†	51 (43%)‡	886 (93%)‡	24,424 (79%)
Body weight (kg ± SD)	77 ± 20*	78 ± 21‡	69 ± 15†	71 ± 15
Associated conditions				
Cancer	27 (51%)‡	27 (23%)	272 (29%)‡	6,145 (20%)
Uterine	19 (36%)‡	15 (13%)‡	26 (2.7%)*	515 (1.7%)
Metastatic cancer	15 (56%)	9 (33%)	127 (47%)	2,606 (42%)
Pregnancy/puerperium	3 (5.7%)	4 (3.4%)	3 (0.32%)‡	820 (2.7%)
Anemia	38 (72%)‡	51 (43%)	479 (51%)‡	10,980 (36%)
PlC <100,000/μL	0	3 (2.5%)	34 (3.6%)‡	600 (1.9%)
PlC >450,000/μL	10 (19%)‡	6 (5.1%)	62 (6.5%)‡	1,160 (3.8%)
CrCl levels <60 ml/min	13 (25%)‡	26 (22%)‡	638 (67%)‡	14,616 (47%)
Recent major bleeding	6 (11%)‡	7 (5.9%)*	47 (5.0%)‡	645 (2.1%)
Initial VTE presentation				
Pulmonary embolism	30 (57%)	72 (61%)	595 (63%)‡	16,421 (53%)

Comparisons between women who bled vs. those that did not bleed: *$p < 0.05$; †$p < 0.01$; ‡$p < 0.001$.
Abbreviations: SD, standard therapy; PlC, platelet count; CrCl, creatinine clearance; VTE, venous thromboembolism.